Mylan Specialty L.P is engaged in the development, manufacture, and marketing of prescription drug products for the treatment of respiratory diseases, life-threatening allergic reactions, and ...
Mylan Specialty, a subsidiary of Mylan Inc. (NASDAQ: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, life-threatening allergic reactions and psychiatric disorders.
Mylan Specialty L.P. is commemorating the 25 th anniversary of the FDA approval of the EpiPen Auto-Injector. This innovative epinephrine auto-injector, the first of its kind, was developed for the emergency treatment of severe allergic reactions (anaphylaxis).
About Mylan Specialty L.P. When a peanut or a bee threatens your very existence, Mylan Specialty (formerly Dey Pharma) is ready to save the day. Its specialty prescription drugs treat severe allergic reactions, respiratory diseases, and pschyiatric disorders.
Mylan Specialty L.P. is a Florida Foreign Limited Partnership filed on March 6, 2013 . The company's filing status is listed as Active and its File Number is B13000000064 . The Registered Agent on file for this company is Corporation Service Company and is located at 1201 Hays Street, Tallahassee, FL 32301.
To contact Mylan Specialty L.P, please visit . Company data is provided by S&P Global Market Intelligence. Company data is provided by S&P Global Market Intelligence. Please use this form to ...
I would like to receive relevant information via email from MPR / Haymarket Medical Network. By registering you consent to the collection and use of your information to provide the products and ...
Pharmaceutical companies Mylan Inc. and Mylan Specialty L.P. have agreed to pay $465 million to resolve claims that they violated the False Claims Act by knowingly misclassifying EpiPen as a generic drug to avoid paying rebates owed primarily to Medicaid, the Justice Department announced today.
- related to Mylan Specialty, L.P